With advancing age, senescent fat cell progenitors, or preadipocytes, accumulate and lead to impaired adipogenesis and increased inflammation. We propose this contributes to age-related fat tissue dysfunction. Senescent preadipocytes acquire a senescence-associated secretory phenotype (SASP), which entails secretion of pro-inflammatory cytokines, chemokines, and ECM-remodeling proteases. We found that lL-6 and TNFa, both of which inhibit adipogenesis, activate Jak/Stat, increase C/EBPB, and further induce senescence and the SASP. Strikingly, by inhibiting Jak, we rescued the age-related decline in preadipocyte differentiation, reduced the SASP in preadipocytes from old animals, and prevented induction of senescence and the SASP in cells from young animals caused by cytokines. Our hypothesis is that inhibiting Jak/Stat will ameliorate the age-related preadipocyte senescent pro-inflammatory secretory phenotype and restore fat tissue function. We propose the following Specific Aims:
Aim 1 Dissect mechanisms responsible for preadipocyte senescence and the secretory phenotype. We will focus on IL-6 TNFa, Jaks, and Stats in preadipocytes from animals of different ages. We will determine how cytokines and Jak/Stat components are related to the SASP. We will test if these relations are causal by inhibiting Jaks and varying upstream activators and downstream targets. We will test the role of senescent preadipocytes by selectively eliminating them from populations cultured from INK-ATTAC mice.
Aim 2 Determine functional consequences of the preadipocyte SASP. Based on our characterization of the preadipocyte SASP, we will determine how the SASP interferes with adipogenesis, impairs fat cell glucose uptake, and promotes macrophage migration. We will determine how interfering with Jak and mTOR corrects functional deficits at the cellular level.
Aim 3 Rescue age-related functional declines by interfering with Jak/Stat-mediated senescence. We will test if Jak inhibitors reduce frailty, senescence, inflammation, and dysfunction in aging animals. To determine if benefits of Jak inhibition occur through effects on senescent cells, we will compare the impact of inhibiting Jak to the other interventions in this PPG and test if inhibiting Jak reduces fat tissue senescent cell abundance and inflammation in subjects enrolled in a Jak inhibitor clinical trial. This research will fill fundamental gaps in understanding how cellular senescence and inflammation are linked in fat tissue and the functional consequences of this. Targeting the fat tissue SASP using Jak inhibitors that are already in clinical use for other indications is a promising path to developing interventions for age-related frailty.

Public Health Relevance

Fat tissue dysfunction increases with aging, contributing to diabetes and other age-related chronic disorders. We found that senescent cells, which release factors that cause tissue inflammation, accumulate in fat with aging. We devised ways to eliminate these cells, prevent their spread, or reduce their production of factors that cause tissue dysfunction. We will test if these interventions restore fat tissue function in old age.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG041122-03
Application #
8665358
Study Section
Special Emphasis Panel (ZAG1-ZIJ-2)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
3
Fiscal Year
2014
Total Cost
$410,378
Indirect Cost
$152,278
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Comisford, Ross; Lubbers, Ellen R; Householder, Lara A et al. (2016) Growth Hormone Receptor Antagonist Transgenic Mice Have Increased Subcutaneous Adipose Tissue Mass, Altered Glucose Homeostasis and No Change in White Adipose Tissue Cellular Senescence. Gerontology 62:163-72
Xu, Ming; Tchkonia, Tamar; Kirkland, James L (2016) Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction. Pharmacol Res 111:152-4
Baker, Darren J; Childs, Bennett G; Durik, Matej et al. (2016) Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530:184-9
Palmer, Allyson K; Kirkland, James L (2016) Aging and adipose tissue: potential interventions for diabetes and regenerative medicine. Exp Gerontol 86:97-105
Schafer, Marissa J; White, Thomas A; Evans, Glenda et al. (2016) Exercise Prevents Diet-Induced Cellular Senescence in Adipose Tissue. Diabetes 65:1606-15
Kirkland, James L (2016) Translating the Science of Aging into Therapeutic Interventions. Cold Spring Harb Perspect Med 6:a025908
Ye, Hong; Wang, Xiaofang; Sussman, Caroline R et al. (2016) Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies. J Am Soc Nephrol 27:1312-20
Huffman, Derek M; Schafer, Marissa J; LeBrasseur, Nathan K (2016) Energetic interventions for healthspan and resiliency with aging. Exp Gerontol 86:73-83
Zhu, Yi; Tchkonia, Tamara; Fuhrmann-Stroissnigg, Heike et al. (2016) Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15:428-35
Xu, Ming; Palmer, Allyson K; Ding, Husheng et al. (2015) Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife 4:e12997

Showing the most recent 10 out of 44 publications